Pub Date : 2026-01-01Epub Date: 2026-02-02DOI: 10.1007/s40429-025-00712-0
Jane Metrik, Nicholas Bush, Rachel L Gunn, Denis M McCarthy
Purpose of review: To examine cannabis-induced effects on driving performance. Prior systematic reviews consistently reveal that Δ⁹-tetrahydrocannabinol (THC) impairs driving performance. The present narrative review summarized evidence on the acute and residual effects of cannabis on driving performance from controlled experimental research completed in the past five years. Expanding on prior research, recent studies examine individual and combined effects of THC and cannabidiol (CBD), combined effects of cannabis and alcohol, and a variety of cannabis administration modes.
Recent findings: Cannabis with THC acutely impairs driving without significant residual deficits. CBD does not acutely impair driving performance, although relatively low doses (< 300 mg) were used in most studies. The combination of alcohol and THC results in additive effects that amplifies impairment. In line with prior research findings, cannabis-induced driving impairment is consistently observed within the first hour after use and impairment remains detectable for ~ 4-5 h post-inhalation; studies testing oral and sublingual cannabis administrations were sparse. Participants were willing and ready to drive shortly after using cannabis while their driving skills were objectively impaired.
Summary: Despite clear evidence of cannabis-induced driving impairment, a consistent impairment standard that can be used outside the laboratory is lacking. More research focused on sensitive biomarkers combined with technologically-advanced behavioral methods is needed to improve the precision and accuracy in determining cannabis-induced driving impairment. Future studies should focus on novel oral and oromucosal formulations emerging on the legal cannabis market.
{"title":"Recent Advances in the Science of Cannabis-Impaired Driving.","authors":"Jane Metrik, Nicholas Bush, Rachel L Gunn, Denis M McCarthy","doi":"10.1007/s40429-025-00712-0","DOIUrl":"10.1007/s40429-025-00712-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>To examine cannabis-induced effects on driving performance. Prior systematic reviews consistently reveal that Δ⁹-tetrahydrocannabinol (THC) impairs driving performance. The present narrative review summarized evidence on the acute and residual effects of cannabis on driving performance from controlled experimental research completed in the past five years. Expanding on prior research, recent studies examine individual and combined effects of THC and cannabidiol (CBD), combined effects of cannabis and alcohol, and a variety of cannabis administration modes.</p><p><strong>Recent findings: </strong>Cannabis with THC acutely impairs driving without significant residual deficits. CBD does not acutely impair driving performance, although relatively low doses (< 300 mg) were used in most studies. The combination of alcohol and THC results in additive effects that amplifies impairment. In line with prior research findings, cannabis-induced driving impairment is consistently observed within the first hour after use and impairment remains detectable for ~ 4-5 h post-inhalation; studies testing oral and sublingual cannabis administrations were sparse. Participants were willing and ready to drive shortly after using cannabis while their driving skills were objectively impaired.</p><p><strong>Summary: </strong>Despite clear evidence of cannabis-induced driving impairment, a consistent impairment standard that can be used outside the laboratory is lacking. More research focused on sensitive biomarkers combined with technologically-advanced behavioral methods is needed to improve the precision and accuracy in determining cannabis-induced driving impairment. Future studies should focus on novel oral and oromucosal formulations emerging on the legal cannabis market.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"13 1","pages":"8"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12864297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-24DOI: 10.1007/s40429-025-00628-9
Fatima Dobani, Emma S Schillinger, Alison Vrabec, Katherine M Kidwell, Aesoon Park
Purpose of review: This paper aimed to estimate pooled bi-directional associations between multidimensional sleep health and substance use among youth and investigate whether these associations differed as a function of race/ethnicity.
Recent findings: Empirical observational studies providing quantitative data on the association of sleep health (duration [sleep obtained per 24 hours], satisfaction [subjective assessment of sleep], alertness [ability to maintain attentive wakefulness], and timing [placement of sleep]) and substance use (i.e., alcohol and cannabis), and racial/ethnic demographic information among U.S. youth (10-25) were identified through a systematic literature search. Random effects meta-analyses were conducted using 95 effect sizes extracted from 38 studies.
Summary: We found evidence for a bi-directional relationship between total sleep duration and substance use. Sleep satisfaction predicted substance use, but findings were inconclusive whether substance use predicted sleep satisfaction. Sleep alertness predicted alcohol (but not cannabis) use, whereas sleep timing predicted cannabis (but not alcohol) use. Nuanced racial/ethnic differences were also found in these sleep-substance use relationships, which differed across sleep domains and types of substance.
{"title":"A Meta-Analysis of Bi-Directional Associations between Sleep Health and Substance Use among U.S. Youth: Racial/Ethnic Differences.","authors":"Fatima Dobani, Emma S Schillinger, Alison Vrabec, Katherine M Kidwell, Aesoon Park","doi":"10.1007/s40429-025-00628-9","DOIUrl":"10.1007/s40429-025-00628-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>This paper aimed to estimate pooled bi-directional associations between multidimensional sleep health and substance use among youth and investigate whether these associations differed as a function of race/ethnicity.</p><p><strong>Recent findings: </strong>Empirical observational studies providing quantitative data on the association of sleep health (duration [sleep obtained per 24 hours], satisfaction [subjective assessment of sleep], alertness [ability to maintain attentive wakefulness], and timing [placement of sleep]) and substance use (i.e., alcohol and cannabis), and racial/ethnic demographic information among U.S. youth (10-25) were identified through a systematic literature search. Random effects meta-analyses were conducted using 95 effect sizes extracted from 38 studies.</p><p><strong>Summary: </strong>We found evidence for a bi-directional relationship between total sleep duration and substance use. Sleep satisfaction predicted substance use, but findings were inconclusive whether substance use predicted sleep satisfaction. Sleep alertness predicted alcohol (but not cannabis) use, whereas sleep timing predicted cannabis (but not alcohol) use. Nuanced racial/ethnic differences were also found in these sleep-substance use relationships, which differed across sleep domains and types of substance.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-29DOI: 10.1007/s40429-025-00625-y
Nicole D Fitzgerald, Joseph J Palamar, Linda B Cottler
Purpose of review: As the overdose crisis evolves, it is important to monitor fentanyl consumption patterns. This review provides an overview of recent findings regarding illegally manufactured fentanyl (IMF) availability, use, and associated harms in the US.
Recent findings: Availability of IMF has increased, especially in pill form, and the increasing adulteration of IMF with veterinary tranquilizers such as xylazine complicates overdose response. Prevalence in the general population based on self-reported IMF use is rare, and likely underestimated. Transitions from injection to smoking have been documented in recent years, particularly in the western US. Fentanyl-stimulant polysubstance use has also been observed increasingly among IMF-related overdose deaths.
Summary: Shifts in routes of administration, availability of counterfeit pills containing fentanyl, and common adulterants add complexity to the landscape of IMF use and related harms. Additional data is needed for monitoring changes in consumption patterns to inform prevention and harm reduction efforts.
{"title":"Use of Illegally Manufactured Fentanyl in the United States: Current Trends.","authors":"Nicole D Fitzgerald, Joseph J Palamar, Linda B Cottler","doi":"10.1007/s40429-025-00625-y","DOIUrl":"10.1007/s40429-025-00625-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>As the overdose crisis evolves, it is important to monitor fentanyl consumption patterns. This review provides an overview of recent findings regarding illegally manufactured fentanyl (IMF) availability, use, and associated harms in the US.</p><p><strong>Recent findings: </strong>Availability of IMF has increased, especially in pill form, and the increasing adulteration of IMF with veterinary tranquilizers such as xylazine complicates overdose response. Prevalence in the general population based on self-reported IMF use is rare, and likely underestimated. Transitions from injection to smoking have been documented in recent years, particularly in the western US. Fentanyl-stimulant polysubstance use has also been observed increasingly among IMF-related overdose deaths.</p><p><strong>Summary: </strong>Shifts in routes of administration, availability of counterfeit pills containing fentanyl, and common adulterants add complexity to the landscape of IMF use and related harms. Additional data is needed for monitoring changes in consumption patterns to inform prevention and harm reduction efforts.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12346689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-07DOI: 10.1007/s40429-025-00620-3
Alyssa Michel, Dongyu Kang, Roger B Fillingim, Nicholas L Balderston, Dale S Bond, Vaughn R Steele
Purpose of review: Both substance use disorders (SUD) and chronic pain are highly prevalent, require new effective interventions, and share similar underlying neurocircuitry. A promising intervention for both is repetitive transcranial magnetic stimulation (rTMS) which is a tool to modulate brain circuits. In this narrative review, we surveyed the current state of rTMS used to address SUDs and chronic pain by focusing on 132 reports published since 2010.
Recent findings: The field agrees that rTMS application in these clinical samples is safe and potentially effective, even in co-occurring disease or with recent substance use. Overall, the pain field has come to a stronger consensus about how best to apply rTMS to reduce diverse chronic pain conditions compared to the SUD field. We argue for standardization of methods within fields to rapidly address each clinical group. Such a standardization will require a concerted effort to test applications head-to-head to evaluate relative efficacy across applications. A coordinated effort in this regard is needed between research groups and funding agencies to accomplish this goal.
Summary: One of the most effective steps the field can take toward this goal is to measure the neuromechanisms that underlie SUD and pain before and after an rTMS intervention. Only 18% of reviewed reports included any brain measurement such as functional magnetic resonance imaging, electroencephalography, and event-related potentials. We argue that such measurements are essential for optimizing rTMS as an intervention for clinical populations. If rTMS is ostensibly applied to modulate neurocircuits, measurement of those circuits to verify, iterate, and optimize application is fundamental for developing effective treatments.
{"title":"Repetitive transcranial magnetic stimulation for substance use disorders and chronic pain: A review of the evidence and call for increased mechanistic understanding.","authors":"Alyssa Michel, Dongyu Kang, Roger B Fillingim, Nicholas L Balderston, Dale S Bond, Vaughn R Steele","doi":"10.1007/s40429-025-00620-3","DOIUrl":"10.1007/s40429-025-00620-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Both substance use disorders (SUD) and chronic pain are highly prevalent, require new effective interventions, and share similar underlying neurocircuitry. A promising intervention for both is repetitive transcranial magnetic stimulation (rTMS) which is a tool to modulate brain circuits. In this narrative review, we surveyed the current state of rTMS used to address SUDs and chronic pain by focusing on 132 reports published since 2010.</p><p><strong>Recent findings: </strong>The field agrees that rTMS application in these clinical samples is safe and potentially effective, even in co-occurring disease or with recent substance use. Overall, the pain field has come to a stronger consensus about how best to apply rTMS to reduce diverse chronic pain conditions compared to the SUD field. We argue for standardization of methods within fields to rapidly address each clinical group. Such a standardization will require a concerted effort to test applications head-to-head to evaluate relative efficacy across applications. A coordinated effort in this regard is needed between research groups and funding agencies to accomplish this goal.</p><p><strong>Summary: </strong>One of the most effective steps the field can take toward this goal is to measure the neuromechanisms that underlie SUD and pain before and after an rTMS intervention. Only 18% of reviewed reports included any brain measurement such as functional magnetic resonance imaging, electroencephalography, and event-related potentials. We argue that such measurements are essential for optimizing rTMS as an intervention for clinical populations. If rTMS is ostensibly applied to modulate neurocircuits, measurement of those circuits to verify, iterate, and optimize application is fundamental for developing effective treatments.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12467114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-27DOI: 10.1007/s40429-025-00632-z
Molly Magill, Samuel Meisel, David I K Moniz-Lewis, Stephan Maisto, Katie Witkiewitz
Purpose of review: This review examines self-efficacy and traces the construct from theory and operationalization to clinical practice and intervention design in addiction science.
Recent findings: Self-efficacy is a construct with a strong theoretical and methodological foundation. While evidence for self-efficacy as a statistical mediator in the context of clinical trials of addictions treatments is mixed, it is most conclusive in within-condition, non-experimental designs. Consistency in empirical support across research methods, populations, and outcomes strengthens support for self-efficacy as a mechanism of alcohol or other substance consumption outcomes.
Summary: The current review provides evidence for self-efficacy as a mechanism worthy of direct attention in clinical care for alcohol or other substance use disorders. It is likely a common mechanism of human behavior change that can be harnessed in a range of treatment modalities and client-identified goals. Future work should target self-efficacy directly in intervention development, implementation, and dissemination.
{"title":"Self-Efficacy as a Mechanism of Behavior Change in Addiction Science and Practice.","authors":"Molly Magill, Samuel Meisel, David I K Moniz-Lewis, Stephan Maisto, Katie Witkiewitz","doi":"10.1007/s40429-025-00632-z","DOIUrl":"https://doi.org/10.1007/s40429-025-00632-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review examines <i>self-efficacy</i> and traces the construct from theory and operationalization to clinical practice and intervention design in addiction science.</p><p><strong>Recent findings: </strong>Self-efficacy is a construct with a strong theoretical and methodological foundation. While evidence for self-efficacy as a statistical mediator in the context of clinical trials of addictions treatments is mixed, it is most conclusive in within-condition, non-experimental designs. Consistency in empirical support across research methods, populations, and outcomes strengthens support for self-efficacy as a mechanism of alcohol or other substance consumption outcomes.</p><p><strong>Summary: </strong>The current review provides evidence for self-efficacy as a mechanism worthy of direct attention in clinical care for alcohol or other substance use disorders. It is likely a common mechanism of human behavior change that can be harnessed in a range of treatment modalities and client-identified goals. Future work should target self-efficacy directly in intervention development, implementation, and dissemination.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-02-25DOI: 10.1007/s40429-025-00621-2
Jeremy E Solly, Lucy Albertella, Konstantinos Ioannidis, Naomi A Fineberg, Jon E Grant, Samuel R Chamberlain
Purpose of review: Behavioural addictions involve loss of control over initially rewarding behaviours, which continue despite adverse consequences. Theoretical models suggest that these patterns of behaviour evolve over time, with compulsive and habitual behaviours held to reflect a loss of behavioural control. Compulsivity can be broadly described as a propensity for (or engagement in) repetitive behaviours that are not aligned with overall goals. Here, we consider whether compulsivity is associated with behavioural addictions at different stages of their development, based on self-report and neurocognitive measures.
Recent findings: This review found that there is initial evidence that compulsive traits might predispose individuals to engage in problematic behaviours, and that self-report and neurocognitive measures of compulsivity are associated with severity of problematic behaviours even in the early stages of behavioural addictions. In the later stages of behavioural addiction, there is strong evidence for an association of gambling disorder with cognitive inflexibility, but less evidence for an association between compulsivity and other types of behavioural addiction.
Summary: Moving forwards, well-powered longitudinal studies, including studies using ecological momentary assessment (EMA), will be important in robustly developing our understanding of how compulsivity is related to behavioural addictions over their timecourse.
{"title":"Recent advances in understanding how compulsivity is related to behavioural addictions over their timecourse.","authors":"Jeremy E Solly, Lucy Albertella, Konstantinos Ioannidis, Naomi A Fineberg, Jon E Grant, Samuel R Chamberlain","doi":"10.1007/s40429-025-00621-2","DOIUrl":"10.1007/s40429-025-00621-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Behavioural addictions involve loss of control over initially rewarding behaviours, which continue despite adverse consequences. Theoretical models suggest that these patterns of behaviour evolve over time, with compulsive and habitual behaviours held to reflect a loss of behavioural control. Compulsivity can be broadly described as a propensity for (or engagement in) repetitive behaviours that are not aligned with overall goals. Here, we consider whether compulsivity is associated with behavioural addictions at different stages of their development, based on self-report and neurocognitive measures.</p><p><strong>Recent findings: </strong>This review found that there is initial evidence that compulsive traits might predispose individuals to engage in problematic behaviours, and that self-report and neurocognitive measures of compulsivity are associated with severity of problematic behaviours even in the early stages of behavioural addictions. In the later stages of behavioural addiction, there is strong evidence for an association of gambling disorder with cognitive inflexibility, but less evidence for an association between compulsivity and other types of behavioural addiction.</p><p><strong>Summary: </strong>Moving forwards, well-powered longitudinal studies, including studies using ecological momentary assessment (EMA), will be important in robustly developing our understanding of how compulsivity is related to behavioural addictions over their timecourse.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":"26"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-27DOI: 10.1007/s40429-025-00703-1
Meghan Bridgid Moran, Saraniya Tharmarajah, Lauren Czaplicki, Johannes Thrul, Tory R Spindle, Ryan Vandrey, Jennifer L Pearson, C Austin Zamarripa
Purpose of review: In the U.S., cannabis products containing at least 0.3% tetrahydrocannabinol (THC), are legal for adult use in 22 states (including the District of Columbia) and in 16 additional states for medicinal use. There is a growing body of literature to understand how these products are marketed. The objective of this narrative review is to summarize recent research examining cannabis advertising. We characterized the research reviewed across three primary domains: (1) content of cannabis advertising; (2) prevalence of cannabis advertising exposure; and (3) effects of cannabis advertising on user perceptions.
Recent findings: Research indicates that cannabis is marketed in a variety of ways, including via tactics (e.g., price promotions) found to be effective in increasing use of other commercial products (e.g., tobacco). Moreover, cannabis marketing tactics may be appealing to youth or mislead consumers via unsubstantiated health claims. Exposure to cannabis advertising is common among both youth and adults, occurring through a variety of pathways including storefront signage, social media and billboards. Finally, several studies have found associations between exposure to cannabis marketing and cannabis use; however, studies designed to estimate causal effects of exposure were limited, warranting additional research in this area.
Summary: Understanding the prevalence and effects of exposure to cannabis advertising, along with the content of this advertising, can inform the operationalization and implementation of regulations and interventions designed to mitigate harms associated with advertising exposure.
{"title":"A Narrative Review of Research on Cannabis Advertising in the United States.","authors":"Meghan Bridgid Moran, Saraniya Tharmarajah, Lauren Czaplicki, Johannes Thrul, Tory R Spindle, Ryan Vandrey, Jennifer L Pearson, C Austin Zamarripa","doi":"10.1007/s40429-025-00703-1","DOIUrl":"10.1007/s40429-025-00703-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>In the U.S., cannabis products containing at least 0.3% tetrahydrocannabinol (THC), are legal for adult use in 22 states (including the District of Columbia) and in 16 additional states for medicinal use. There is a growing body of literature to understand how these products are marketed. The objective of this narrative review is to summarize recent research examining cannabis advertising. We characterized the research reviewed across three primary domains: (1) content of cannabis advertising; (2) prevalence of cannabis advertising exposure; and (3) effects of cannabis advertising on user perceptions.</p><p><strong>Recent findings: </strong>Research indicates that cannabis is marketed in a variety of ways, including via tactics (e.g., price promotions) found to be effective in increasing use of other commercial products (e.g., tobacco). Moreover, cannabis marketing tactics may be appealing to youth or mislead consumers via unsubstantiated health claims. Exposure to cannabis advertising is common among both youth and adults, occurring through a variety of pathways including storefront signage, social media and billboards. Finally, several studies have found associations between exposure to cannabis marketing and cannabis use; however, studies designed to estimate causal effects of exposure were limited, warranting additional research in this area.</p><p><strong>Summary: </strong>Understanding the prevalence and effects of exposure to cannabis advertising, along with the content of this advertising, can inform the operationalization and implementation of regulations and interventions designed to mitigate harms associated with advertising exposure.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":"92"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12743689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145858490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-02-19DOI: 10.1007/s40429-025-00634-x
J Morris, D K Richards, I P Albery
Purpose of review: Alcohol problem recognition reflects the extent to which a person with any level of problematic alcohol use (PAU), including hazardous alcohol use, acknowledges the associated risks/harms as potentially/actually problematic with a relative degree of objectivity. Notably, alcohol problem recognition is typically low amongst people with PAU not engaged in treatment or support. This review evaluates existing PAU problem recognition measures and related concepts such as ambivalence, readiness to change, motivation, cognitive biases and other self-evaluative appraisal processes.
Recent findings: Alcohol problem recognition has been operationalised via various measures but is often conflated with other related but theoretically distinct concepts. Limited conceptual work examines the nature of problem recognition as a discrete concept and its function in relation to behaviour change outcomes and key variables.
Summary: Problem recognition is proposed as an important theoretically distinct process that warrants further conceptual development and testing for advancing understanding of change processes across the PAU spectrum.
{"title":"Problem Recognition as A Discrete Concept for Change Processes in Problematic Alcohol Use.","authors":"J Morris, D K Richards, I P Albery","doi":"10.1007/s40429-025-00634-x","DOIUrl":"10.1007/s40429-025-00634-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Alcohol problem recognition reflects the extent to which a person with any level of problematic alcohol use (PAU), including hazardous alcohol use, acknowledges the associated risks/harms as potentially/actually problematic with a relative degree of objectivity. Notably, alcohol problem recognition is typically low amongst people with PAU not engaged in treatment or support. This review evaluates existing PAU problem recognition measures and related concepts such as ambivalence, readiness to change, motivation, cognitive biases and other self-evaluative appraisal processes.</p><p><strong>Recent findings: </strong>Alcohol problem recognition has been operationalised via various measures but is often conflated with other related but theoretically distinct concepts. Limited conceptual work examines the nature of problem recognition as a discrete concept and its function in relation to behaviour change outcomes and key variables.</p><p><strong>Summary: </strong>Problem recognition is proposed as an important theoretically distinct process that warrants further conceptual development and testing for advancing understanding of change processes across the PAU spectrum.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":"23"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-12-21DOI: 10.1007/s40429-025-00706-y
Nina Abukahok, Nicole D Fitzgerald, Joseph J Palamar
Purpose of review: Tusi, also known as "pink cocaine," has emerged across nightlife scenes in Latin America, Europe, Australia, and the United States (US). Tusi is typically a drug mixture containing ketamine and 3,4-methylenedioxymethamphetamine (MDMA). Due to tusi's inconsistent chemical makeup, surveillance and harm reduction efforts have proven difficult for researchers and consumers alike. This review synthesizes evidence from peer-reviewed literature, drug checking programs, toxicology reports, and law enforcement data published between 2020 and 2025 to characterize tusi's composition, epidemiology, and associated risks.
Recent findings: Drug checking services in various countries have identified ketamine and MDMA as the main components of tusi with additional substances often added (e.g., synthetic cathinones, cocaine, methamphetamine) in varying combinations. Laboratory data from Spain show that ketamine concentrations in tusi have increased over time. Surveys in Spain and Colombia highlight increases in initiation, polysubstance use involving tusi, and misclassification of its contents. Toxicology and case series reports indicate that harms associated with use stem largely from polysubstance mixtures rather than any single component, yet morbidity and mortality data typically focus on individual drugs detected.
Summary: Tusi exemplifies a novel trend in emerging drugs: it is a blend of substances rather than a single compound, with its identity shaped by its distinctive color and association with nightlife. Its inconsistent composition and frequent co-use with stimulants and dissociatives elevate risk while complicating surveillance. Standardized survey items, expanded drug checking, and improved toxicological monitoring are needed to track and respond to this evolving mixture in the global drug supply.
{"title":"An Update on the Epidemiology of Tusi (\"Pink Cocaine\").","authors":"Nina Abukahok, Nicole D Fitzgerald, Joseph J Palamar","doi":"10.1007/s40429-025-00706-y","DOIUrl":"10.1007/s40429-025-00706-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Tusi, also known as \"pink cocaine,\" has emerged across nightlife scenes in Latin America, Europe, Australia, and the United States (US). Tusi is typically a drug mixture containing ketamine and 3,4-methylenedioxymethamphetamine (MDMA). Due to tusi's inconsistent chemical makeup, surveillance and harm reduction efforts have proven difficult for researchers and consumers alike. This review synthesizes evidence from peer-reviewed literature, drug checking programs, toxicology reports, and law enforcement data published between 2020 and 2025 to characterize tusi's composition, epidemiology, and associated risks.</p><p><strong>Recent findings: </strong>Drug checking services in various countries have identified ketamine and MDMA as the main components of tusi with additional substances often added (e.g., synthetic cathinones, cocaine, methamphetamine) in varying combinations. Laboratory data from Spain show that ketamine concentrations in tusi have increased over time. Surveys in Spain and Colombia highlight increases in initiation, polysubstance use involving tusi, and misclassification of its contents. Toxicology and case series reports indicate that harms associated with use stem largely from polysubstance mixtures rather than any single component, yet morbidity and mortality data typically focus on individual drugs detected.</p><p><strong>Summary: </strong>Tusi exemplifies a novel trend in emerging drugs: it is a blend of substances rather than a single compound, with its identity shaped by its distinctive color and association with nightlife. Its inconsistent composition and frequent co-use with stimulants and dissociatives elevate risk while complicating surveillance. Standardized survey items, expanded drug checking, and improved toxicological monitoring are needed to track and respond to this evolving mixture in the global drug supply.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12826529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146047454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-05-13DOI: 10.1007/s40429-025-00660-9
Shubekshya Upadhyay, Abena Duah, Victoria Francois, Sophia I Allen
Purpose of review: African American individuals in the US have the highest rates of mortality from diseases such as lung cancer, coronary heart disease, and stroke compared with other minoritized people due to tobacco smoking. Evidence-based interventions are useful for reducing the burden of diseases by helping those who smoke to quit. Despite a higher motivation to quit, African American adult smokers have lower success rates and less access to evidence-based interventions. Hence, it is important to study the factors associated with unsuccessful quit attempts among this population and to search the literature for gaps that need to be addressed.
Recent findings: We identified 19 articles that focused on Quitlines and text messaging interventions to help African Americans to quit. The interventions used in the studies were Quitlines, text messaging, telephone counseling and media campaigns. We found that African Americans were more likely to use Quitlines than Whites. Studies indicated that interventions should be tailored according to patient preferences. For example, one of the findings was that participants had mixed feelings about the use of standard and non-standard Quitline services. Individuals aged over 60 years preferred standard services such as telephone counseling and printed materials. However, the younger generation were interested in non-standard services.
Summary: There are only a few studies focused on the use of Quitlines and the utilization of their text messaging service among African Americans. Future studies should focus on the reasons disparities in smoking cessation rates exist among African American individuals and leverage the use of text messaging.
Supplementary information: The online version contains supplementary material available at 10.1007/s40429-025-00660-9.
{"title":"A Scoping Review of Interventions for Tobacco Cessation Among African American Individuals.","authors":"Shubekshya Upadhyay, Abena Duah, Victoria Francois, Sophia I Allen","doi":"10.1007/s40429-025-00660-9","DOIUrl":"10.1007/s40429-025-00660-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>African American individuals in the US have the highest rates of mortality from diseases such as lung cancer, coronary heart disease, and stroke compared with other minoritized people due to tobacco smoking. Evidence-based interventions are useful for reducing the burden of diseases by helping those who smoke to quit. Despite a higher motivation to quit, African American adult smokers have lower success rates and less access to evidence-based interventions. Hence, it is important to study the factors associated with unsuccessful quit attempts among this population and to search the literature for gaps that need to be addressed.</p><p><strong>Recent findings: </strong>We identified 19 articles that focused on Quitlines and text messaging interventions to help African Americans to quit. The interventions used in the studies were Quitlines, text messaging, telephone counseling and media campaigns. We found that African Americans were more likely to use Quitlines than Whites. Studies indicated that interventions should be tailored according to patient preferences. For example, one of the findings was that participants had mixed feelings about the use of standard and non-standard Quitline services. Individuals aged over 60 years preferred standard services such as telephone counseling and printed materials. However, the younger generation were interested in non-standard services.</p><p><strong>Summary: </strong>There are only a few studies focused on the use of Quitlines and the utilization of their text messaging service among African Americans. Future studies should focus on the reasons disparities in smoking cessation rates exist among African American individuals and leverage the use of text messaging.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40429-025-00660-9.</p>","PeriodicalId":52300,"journal":{"name":"Current Addiction Reports","volume":"12 1","pages":"46"},"PeriodicalIF":4.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}